Clinical efficacy of ezetimibe combined with rosuvastatin in the treatment of patients with high cholesterol and cardiovascular risk
依折麦布联合瑞舒伐他汀治疗高胆固醇血症合并心血管高危患者的临床效果

摘要

目的 分析讨论依折麦布联合瑞舒伐他汀治疗高胆固醇血症合并心血管高危患者的临床效果。方法选择我院2022年1月-2023年1月所接收的100例高胆固醇血症合并心血管高危患者为研究对象，平均分为观察组（依折麦布联合瑞舒伐他汀治疗）与对照组（依折麦布治疗），比较两组在治疗前后的颈动脉硬化情况和血浆脂蛋白相关磷脂酶 A2与血脂情况，以及治疗效果。结果 1.治疗后观察组斑块Crouse 积分与颈动脉内膜中层厚度（3.05±0.32分、0.89±0.51mm）低于对照组，颈动脉内径（7.89±1.54mm）高于对照组（P<0.05）；2.治疗后观察组血浆脂蛋白相关磷脂酶 A2指标与血脂（163.12±12.59μg/L、1.72±0.32mmol/L、1.67±0.14mmol/L、4.02±0.95mmol/L、1.05±0.28mmol/L）均优于对照组（P<0.05）；3.观察组治疗效果（94.0%）比对照组高，（P<0.05）。结论 依折麦布联合瑞舒伐他汀在高胆固醇血症合并心血管高危患者治疗中效果明显，值得广泛推广与应用。

Abstract

Objective To analyze and discuss the clinical efficacy of ezetimibe combined with rosuvastatin in the treatment of patients with high cholesterol and cardiovascular risk.
Methods 100 patients with high cholesterol and cardiovascular risk admitted to our hospital from January 2022 to January 2023 were selected as the research subjects. They were evenly divided into an observation group (treated with ezetimibe combined with rosuvastatin) and a control group (treated with ezetimibe). The carotid atherosclerosis, plasma lipoprotein related phospholipase A2, and blood lipid levels before and after treatment were compared between the two groups, as well as the treatment effect.
Results After treatment, the Crouse score and carotid intima-media thickness (3.05 ± 0.32 points, 0.89 ± 0.51mm) of the observation group were lower than those of the control group, and the carotid artery diameter (7.89 ± 1.54mm) was higher than that of the control group (P<0.05); 2. After treatment, the plasma lipoprotein related phospholipase A2 index and blood lipids in the observation group (163.12 ± 12.59 μ g/L, 1.72 ± 0.32mmol/L, 1.67 ± 0.14mmol/L, 4.02 ± 0.95mmol/L, 1.05 ± 0.28mmol/L) were better than those in the control group (P<0.05); The treatment effect of the observation group (94.0%) was higher than that of the control group, (P<0.05).
Conclusion   The combination of ezetimibe and rosuvastatin is effective in the treatment of patients with high cholesterol and cardiovascular risk, and is worthy of wide promotion and application.